Please login to the form below

Not currently logged in
Email:
Password:

Jazz Pharmaceuticals

This page shows the latest Jazz Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

Jazz Pharmaceuticals has gained EU approval for Vyxeos, its treatment for adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). ... or AML with myelodysplasia-related

Latest news

  • Sanofi’s rare blood disorder drug Cablivi set for European approval Sanofi’s rare blood disorder drug Cablivi set for European approval

    Jazz Pharmaceuticals’ Vyxeos (liposomal daunorubicin/cytarabine) was the fourth orphan disease drug to be recommended by the CHMP, getting the nod for the treatment of newly-diagnosed acute myeloid leukaemia (AML). ... changes in the EU, according to

  • Novartis gets EU nod for leukaemia drug Rydapt Novartis gets EU nod for leukaemia drug Rydapt

    Jazz Pharmaceuticals got the nod for Vyxeos – a fixed -dose combination of cytarabine and daunorubicin that became the first drug in the US for newly diagnosed therapy-related AML (t-AML)

  • Jazz Pharma bags FDA approval for rare disease drug Jazz Pharma bags FDA approval for rare disease drug

    The US FDA has given the green light for Jazz Pharma's Defitelio, adding another product to the company's stable of rare disease therapies. ... Jazz acquired Defitelio as part of its $1bn purchase of Italy's Gentium in 2013.

  • Shire drawn into Luxembourg tax haven exposé Shire drawn into Luxembourg tax haven exposé

    Other pharma companies appearing in an ICIJ database of leaked documents - related to tax rulings that have been approved by Luxembourg officials - include Abbott, Covidien, EUSA Pharma (now Jazz Pharmaceuticals), GE,

  • SMC: Celgene's Abraxane 'too expensive' for Scotland SMC: Celgene's Abraxane 'too expensive' for Scotland

    Drugs that received positive opinions included Janssen's Invokana (canagliflozin) for type 2 diabetes, Jazz Pharmaceuticals' Defitelio (defibrotide) for liver disease, GSK's respiratory combination Relvar Ellipta (fluticasone furoate / vilanterol)

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Jazz Pharmaceuticals paid $15m in upfront and option payments to Pfenex for the rights to a portfolio of early stage products in haematology/oncology. ... Sprint BioScience/ Petre Pharma. PIP4K2a inhibitor programme. Licence. 240. Pfenex/ Jazz

  • Pharma deals in March 2015 Pharma deals in March 2015

    The other deal of interest is the re-emergence of EUSA Pharma with products acquired from Jazz Pharmaceuticals. ... investor, Essex Woodlands, has bought back products worth $27m and the EUSA Pharma name from Jazz for an undisclosed amount.

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    3, 080. Cosmo Technologies/ Salix Pharmaceuticals. Merger (tax inversion)    . Portfolio of treatments for gastrointestinal disease and disorders. ... 360. Sigma-Tau/ Jazz Pharmaceuticals. Regaining rights. Defibrotide for severe hepatic

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    490. Aerial BioPharma/ Jazz Pharmaceuticals. Product rights. Jazz gain access to ADX N05 for treatment of narcolepsy, SK Biopharmaceuticals retain some Asian rights, upfront of $125m, Aerial and SK receive milestones ... 100. Cancer Prevention

  • Pharma deals during September 2012 Pharma deals during September 2012

    Dual-affinity re-targeting (DART) platform technology for cancer targets. 1, 100. Selexys Pharmaceuticals  / Novartis Pharmaceuticals. ... Jazz Pharmaceuticals / Meda. Division acquisition. Women's health division. 95. NextMed (Apricus Bio)   / Takeda

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • EUSA Pharma appoints Lee Morley as its new chief executive EUSA Pharma appoints Lee Morley as its new chief executive

    Morton originally founded EUSA in 2005, leading it until its 2012 acquisition by Jazz Pharmaceuticals for $700m and then taking the reins again last month when EUSA was once again launched ... business. Prior to his time with Jazz, and before that the pre

  • EUSA Pharma founder to chair Glide Pharma EUSA Pharma founder to chair Glide Pharma

    EUSA was sold to Jazz Pharmaceuticals in 2012 for $700m. His other entrepreneurial experience in the industry includes founding Zeneus Pharma, which was acquired by Cephalon for $360m.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics